CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells
Frontiers in Immunology · 09.01.2023 · 13
DOI: 10.3389/fimmu.2022.1090959 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 09.01.2023. Verfasst von Simone Thomas und 1 weiteren Autor:innen. Beteiligte Einrichtung: Leibniz Institute for Immunotherapy, Div. Genetic Immunotherapy, Regensburg, Germany. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Antigen, T-Cell, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wilhelm Sander-Stiftung, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Chimeric antigen receptors (CARs) in the canonical “second generation” format provide two signals for inducing T cell effector functions; the primary “signal-1” is provided through the TCR CD3ζ chain and the “signal-2” through a linked costimulatory domain to augment activation. While therapy with second generation CAR T cells can induce remissions of leukemia/lymphoma in a spectacular fashion, CAR T cell persistence is frequently limited which is thought to be due to timely limited activation. Following the “three-signal” dogma for inducing a sustained T cell response, cytokines were supplemented to provide “signal-3” to CAR T cells. Recent progress in the understanding of structural biology and receptor signaling has allowed to engineer cytokines for more selective, fine-tuned stimulation of CAR T cells including an artificial autocrine loop of a transgenic cytokine, a cytokine anchored to the CAR T cell membrane or inserted into the extracellular CAR domain, and a cytokine receptor signaling moiety co-expressed with the CAR or inserted into the CAR endodomain. Here we discuss the recent strategies and options for engineering such “cytokine help intensified CAR” (CHIC) T cells for use in adoptive cell therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leibniz Institute for Immunotherapy, Div. Genetic Immunotherapy, Regensburg, Germany.
- Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
- Chair for Genetic Immunotherapy, University Regensburg, Regensburg, Germany.
Förderung
- Wilhelm Sander-Stiftung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Thomas, S., & Abken, H. (2023). CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.1090959
Vancouver
Thomas S, Abken H. CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells. Frontiers in Immunology. 2023;13. doi:10.3389/fimmu.2022.1090959
BibTeX
@article{Thomas2023,
author = {Thomas, Simone and Abken, Hinrich},
title = {CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells},
journal = {Frontiers in Immunology},
year = {2023},
volume = {13},
doi = {10.3389/fimmu.2022.1090959}
}
EUVIMED